{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:35:58Z","timestamp":1777890958276,"version":"3.51.4"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Junctophilin 3 (JPH3) acts as a tumor suppressor in several cancers; however, the role of JPH3 in anaplastic thyroid cancer (ATC) is still unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Via bioinformatics prediction and verified through Western blot experiments, the expression level of JPH3 in ATC was ascertained. Subsequently, the role of JPH3 in ATC cells was validated via in\u00a0vitro and in\u00a0vivo experiments, and the molecular mechanism of JPH3 in ATC was further illuminated. Eventually, the mechanism of JPH3 on cisplatin (DDP)\u2010resistant ATC cells was probed. The results indicated that JPH3 was highly expressed in thyroid cancer (TC), and the survival period of patients with high expression was significantly curtailed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>JPH3 was upregulated in TC tissues compared with the normal thyroid tissues. Our experiments disclosed that JPH3 acted as an oncogene in ATC cells, facilitating tumor development, and JPH3 can activate the JAK\u2013STAT signaling pathway by upregulation of collagen type XXVI alpha 1 chain (COL26A1), and experiments attested that JPH3 promoted the proliferation, invasion, and migration of ATC cells by activating the JAK\u2013STAT signaling pathway. Further research uncovered that JPH3 was also involved in the process of DDP resistance in ATC cells. By activating the JAK\u2013STAT signaling pathway, JPH3 induced the malignant phenotype of DDP\u2010resistant ATC cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>JPH3 functions as a potent oncogenic driver in ATC, promoting tumor proliferation, invasion, and migration through the activation of the JAK\u2013STAT signaling pathway. This oncoprotein contributes to enhanced DDP resistance in ATC cells via JAK\u2013STAT\u2010mediated mechanisms, offering novel insights into the molecular basis of chemoresistance in this highly aggressive malignancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71750","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:45:06Z","timestamp":1774053906000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<scp>JPH3<\/scp>\n                    Facilitates Cisplatin Resistance in Anaplastic Thyroid Cancer via Activation of the\n                    <scp>JAK<\/scp>\n                    \u2013\n                    <scp>STAT<\/scp>\n                    Signaling Pathway"],"prefix":"10.1002","volume":"15","author":[{"given":"Xiuyan","family":"Wang","sequence":"first","affiliation":[{"name":"The Fourth Department of General Surgery The First Hospital of Harbin  Harbin Heilongjiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Luan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine The Fourth Affiliated Hospital of Harbin Medical University  Harbin Heilongjiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine The First Hospital of Harbin  Harbin Heilongjiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixin","family":"Lian","sequence":"additional","affiliation":[{"name":"The Fourth Department of General Surgery The First Hospital of Harbin  Harbin Heilongjiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0862-1743","authenticated-orcid":false,"given":"Ming","family":"Qi","sequence":"additional","affiliation":[{"name":"The Fourth Department of General Surgery The First Hospital of Harbin  Harbin Heilongjiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"issue":"23","key":"e_1_2_12_2_1","first-page":"2307","article-title":"Biologic and Clinical Perspectives on Thyroid Cancer","volume":"375","author":"Fagin J. A.","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29251"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2021.11.020"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2021.8155"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(05)00005-5"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2014.02.004"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.18185"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2022.12640"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20193377"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2022.04.022"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3758"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-018-0080-4"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-020117-043854"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2012.10.006"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000516053"},{"issue":"2","key":"e_1_2_12_18_1","first-page":"613","article-title":"Apatinib Strengthens the Anti\u2010Tumor Effect of Cisplatin in Thyroid Carcinoma Through Downregulating VEGFR2","volume":"26","author":"Hu Y.","year":"2021","journal-title":"Journal of BUON: Official Journal of the Balkan Union of Oncology"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-23-141"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17228"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgac046"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-014-1030-z"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38581-8"},{"issue":"1","key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13046-019-1161-8","article-title":"Inhibition of ATM Reverses EMT and Decreases Metastatic Potential of Cisplatin\u2010Resistant Lung Cancer Cells Through JAK\/STAT3\/PD\u2010L1 Pathway","volume":"38","author":"Shen M.","year":"2019","journal-title":"Journal of Experimental & Clinical Cancer Research: CR"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71750","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71750","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:50:25Z","timestamp":1777614625000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/cam4.71750"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71750","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-09-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71750"}}